{
  "meta": {
    "title": "Breast_Cancer",
    "url": "https://brainandscalpel.vercel.app/breast-cancer-7093328f.html",
    "scrapedAt": "2025-11-29T18:32:17.244Z"
  },
  "questions": [
    {
      "id": 13640,
      "choices": [
        {
          "id": 54521,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cell proliferation </span></span></span></span></p>"
        },
        {
          "id": 54522,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Promotion of apoptosis </span></span></span></span></p>"
        },
        {
          "id": 54523,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulation of angiogenesis </span></span></span></span></p>"
        },
        {
          "id": 54524,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of cell signaling pathways</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45-year-old woman is diagnosed with breast cancer, and her tumor cells demonstrate overexpression of the HER2/neu proto-oncogene. What is the primary mechanism by which HER2/neu contributes to the pathophysiology of her cancer?</span></span></p>",
      "unique_key": "Q5079178",
      "question_audio": null,
      "question_video": null,
      "map_id": 32331,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Activation of cell signaling pathways</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Proto-oncogene HER2/neu </strong>encodes for a protein that is a <strong>receptor for growth factors</strong>. Its <strong>over-expression </strong>can lead to excessive activation of <strong>downstream cell signaling pathways</strong>, including the<strong> PI3K/Akt and MAPK/Erk pathways</strong>, which promote <strong>cell proliferation and survival</strong>. <strong>HER2/neu overexpression </strong>is associated with a <strong>more aggressive breast cancer phenotype and poorer prognosis.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HER2/neu </strong>is a receptor <strong>tyrosine kinase </strong>that, when<strong> overexpressed</strong>, results in the excessive <strong>activation of downstream signaling pathways</strong>, including <strong>PI3K/Akt and MAPK/Erk</strong>, that are known to<strong> promote cell proliferation and survival.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Inhibition of cell proliferation </strong>is <strong>not </strong>associated with<strong> HER2/neu overexpression; </strong>instead, <strong>HER2/neu </strong>leads to <strong>increased cell proliferation</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Promotion of apoptosis </strong>is <strong>not </strong>a mechanism of<strong> HER2/neu action</strong>. In contrast,<strong> HER2/neu overexpression </strong>tends to confer <strong>resistance to apoptotic signals</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>HER2/neu </strong>overexpression can have d<strong>ownstream effects </strong>that might<strong> indirectly promote angiogenesis</strong>, this is <strong>not the primary action of the proto-oncogene.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Overexpression of the HER2/neu proto-oncogene in breast cancer </strong>leads to the activation of <strong>cell signaling pathways </strong>that promote <strong>cell proliferation and survival. </strong>This overexpression is associated with a<strong> more aggressive disease phenotype and a poorer prognosis</strong>. <strong>Targeted </strong>therapies <strong>against HER2/neu </strong>can be effective in <strong>treating tumors with this over-expression</strong>.</span></span></span></span></p>",
      "correct_choice_id": 54524,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41591,
      "choices": [
        {
          "id": 166052,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
        },
        {
          "id": 166053,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma</span></span></span></p>"
        },
        {
          "id": 166054,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></p>"
        },
        {
          "id": 166055,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman undergoes a breast biopsy after a suspicious mammogram. Histological examination reveals a tumor with lack of tubule formation, discohesive cells and a low mitotic rate. Immunohistochemistry shows positive estrogen receptor (ER) and progesterone receptor (PR) staining. What is the most likely histological type of breast cancer?</span></span></span></p>",
      "unique_key": "Q6982660",
      "question_audio": null,
      "question_video": null,
      "map_id": 32339,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Invasive lobular carcinoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(ILC) is characterized by a <strong>lack of tubule formation</strong>, <strong>discohesive cells </strong>that <strong>infiltrate the stroma in a single-file pattern</strong>, and a <strong>low mitotic rate</strong>. <strong>ILC </strong>is often <strong>ER and PR positive</strong>. The classic <strong>histological features </strong>include a <strong>targetoid appearance</strong>, known as <strong>&quot;Indian file&quot; pattern</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive ductal carcinoma</strong> tends to form <strong>glandular structures </strong>and does not usually present with the &quot;Indian file&quot; pattern of cell arrangement seen in invasive lobular carcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medullary carcinoma</strong> has a <strong>higher mitotic rate </strong>and a <strong>lymphocytic infiltrate</strong>, which differs from the low mitotic rate and discohesive cells described in the biopsy report.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Ductal carcinoma</strong> <strong>in situ</strong> represents an <strong>early form of breast cancer </strong>that is <strong>confined to the ducts </strong>and usually forms duct-like structures, unlike the pattern described.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive lobular carcinoma </strong>is characterized by the <strong>absence of tubule formation</strong>, <strong>discohesive cells</strong>, a <strong>low mitotic rate</strong>, and <strong>positive hormone receptor status</strong>.</span></span></span></p>",
      "correct_choice_id": 166053,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13634,
      "choices": [
        {
          "id": 54497,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17p </span></span></span></span></p>"
        },
        {
          "id": 54498,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17q </span></span></span></span></p>"
        },
        {
          "id": 54499,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13q </span></span></span></span></p>"
        },
        {
          "id": 54500,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13p</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old female presents to her family physician because she palpated a nodule in her left breast during a breast self-examination. She subsequently undergoes a partial mastectomy. The mass is examined by a pathologist who makes a diagnosis of invasive ductal carcinoma. Subsequent genetic testing reveals a mutation of the BRCA2 gene. Of the following, what is the location for this mutation?</span></span></p>",
      "unique_key": "Q5346615",
      "question_audio": null,
      "question_video": null,
      "map_id": 32329,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 13q</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13q&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">indicates the <strong>long arm of chromosome 13</strong>, which is the correct location for the <strong>BRCA2 gene </strong>associated with <strong>breast cancer.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.&nbsp;</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>17p</strong> refers to the <strong>short arm of chromosome 17</strong>, which is where the gene for the <strong>p53 protein </strong>is located,<strong> not BRCA2</strong>. p53 is commonly mutated in many forms of cancer.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>17q</strong> refers to the <strong>long arm of chromosome 17. </strong>This is the <strong>location of the BRCA1 gene</strong>, not BRCA2.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>13p</strong> would refer to the<strong> short arm of chromosome 13</strong>, which is <strong>not </strong>the correct location for the <strong>BRCA2 gene.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> BRCA2 gene </strong>is located on the<strong> long arm of chromosome 13</strong>, at the <strong>cytogenetic band 13q</strong>.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> ed/ 293-4</span></span></strong></span></span></p>",
      "correct_choice_id": 54499,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13648,
      "choices": [
        {
          "id": 54553,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a proto-oncogene</span></span></span></span></p>"
        },
        {
          "id": 54554,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is involved in cell cycle regulation</span></span></span></span></p>"
        },
        {
          "id": 54555,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a tumor suppressor gene</span></span></span></span></p>"
        },
        {
          "id": 54556,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not involved in breast cancer</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with a history of breast cancer. They undergo genetic testing, which reveals a mutation in the BRCA1 gene. Which of the following is true about BRCA1? </span></span></p>",
      "unique_key": "Q8350724",
      "question_audio": null,
      "question_video": null,
      "map_id": 32334,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It is a tumor suppressor gene</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong><em>tumor suppressor gene</em></strong> that encodes for a protein involved in<strong> DNA repair</strong>.<strong> Mutations in the BRCA1 gene </strong>are associated with an<strong> increased risk </strong>of developing<strong><em> breast and ovarian cancers</em></strong>. The<strong> protein </strong>produced by the <strong>BRCA1 gene </strong>is involved in<strong> repairing DNA damage and preventing the formation of tumors</strong>.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a tumor suppressor gene.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA1 </strong>is a tumor suppressor gene that <strong>encodes for a protein involved in DNA repair</strong>.<strong> Mutations </strong>in this gene can lead to<strong> an increased risk of developing breast and ovarian cancers </strong>due to the<strong> loss of effective DNA damage repair</strong>, which can result in the <strong>accumulation of mutations </strong>that contribute to<strong> tumor formation.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is a proto-oncogene.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are <strong>genes </strong>that normally help <strong>cells grow</strong>. When a <strong>proto-oncogene mutates or becomes overactive</strong>, it becomes an<strong> oncogene </strong>and can<strong> lead to cancer</strong>.<strong> BRCA1</strong>, however, is known as a<strong> tumor suppressor gene</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is involved in cell cycle regulation.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While the <strong>BRCA1 gene </strong>does play a role in <strong>cell cycle regulation </strong>as part of its<strong> function </strong>in response to<strong> DNA damage</strong>, it is<strong> more </strong>specifically characterized as a<strong> gene </strong>involved in<strong> DNA repair pathways, </strong>particularly <strong>double-strand break repair</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It is not involved in breast cancer.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect </strong>as mutations in the<strong> BRCA1 gene are well-established risk factors </strong>for<strong> breast cancer</strong>, as well as <strong>ovarian cancer.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA1 gene </strong>is a<strong> tumor suppressor gene </strong>involved in <strong>DNA repair</strong>. <strong>Mutations in BRCA1 </strong>increase the<strong> risk of breast and ovarian cancers </strong>by impairing the repair of DNA damage, which<strong> prevents </strong>the<strong> proper regulation of cell growth and division, </strong>thereby contributing to <strong>tumorigenesis.</strong></span></span></span></span></p>",
      "correct_choice_id": 54555,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16879,
      "choices": [
        {
          "id": 67476,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">p53 </span></span></span></p>"
        },
        {
          "id": 67477,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA-1</span></span></span></p>"
        },
        {
          "id": 67478,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retinoblastoma (Rb)</span></span></span></p>"
        },
        {
          "id": 67479,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H-Ras</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased susceptibility to sporadic breast cancer is likely to be associated with a mutation in the following gene?</span></span></p>",
      "unique_key": "Q9670837",
      "question_audio": null,
      "question_video": null,
      "map_id": 32333,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) p53 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast cancer </strong>can be either <strong>familial </strong>(associated with germline mutation) or <strong>sporadic </strong>(associated with somatic mutation).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>p53 gene</strong>, known for its <strong>role in cell cycle control </strong>and <strong>apoptosis</strong>, is associated with <strong>Li-Fraumeni syndrome</strong>. This <strong>hereditary condition </strong>predisposes <strong>individuals to a variety of cancers</strong>, including <strong>breast cancer</strong>, at an <strong>early age</strong>.&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sporadic breast cancer&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">is associated with mutation in <strong>p53 gene</strong> (p53 defect is present in 40% of human breast cancer as an acquired defect) and <strong>PTEN gene</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since, <strong>incidence of sporadic cancer </strong>is much <strong>more than familial cancer</strong>, so the most <strong>important gene mutation increasing susceptibility </strong>to <strong>breast cancer </strong>should be answered as p53.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The <strong>BRCA1 gene mutation </strong>carries a <strong>high risk for developing breast </strong>and <strong>ovarian cancers</strong>. Individuals with this mutation have a lifetime risk of breast cancer that is significantly higher than the general population.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. While the <strong>Rb gene </strong>is crucial in <strong>controlling cell proliferation </strong>and its <strong>mutation </strong>is primarily <strong>associated with retinoblastoma</strong>, it is not a leading cause of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>H-Ras </strong>is <strong>part of the Ras gene family</strong>; while <strong>mutations </strong>in these <strong>genes can lead to cancer</strong>, they are not typically associated with hereditary breast cancer syndromes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>p53 gene mutation </strong>is </span><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">the <strong>most important gene mutation increasing susceptibility </strong>to <strong>breast cancer</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1051</span></span></strong></p>",
      "correct_choice_id": 67476,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16880,
      "choices": [
        {
          "id": 67480,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">p53 </span></span></span></p>"
        },
        {
          "id": 67481,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA-2</span></span></span></p>"
        },
        {
          "id": 67482,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her 2/Neu gene</span></span></span></p>"
        },
        {
          "id": 67483,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C-myc gene</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female patient presented with a firm mass of 2 &times; 2 cm in the upper outer quadrant of the breast. She gives a family history of ovarian carcinoma. The investigation that needs to be done to assess for mutations is:</span></span></p>",
      "unique_key": "Q4760592",
      "question_audio": null,
      "question_video": null,
      "map_id": 32335,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) BRCA2 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA2</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>tumor suppressor gene</strong>, and <strong>mutations in this gene </strong>are known to significantly <strong>increase the risk of both breast </strong>and <strong>ovarian cancers </strong>in bwith a history suggestive of <strong>hereditary breast </strong>and <strong>ovarian cancer syndrome</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>The p53 gene</strong>, when <strong>mutated</strong>, can lead to a <strong>variety of cancers</strong>; however, in the context of a family history suggesting a hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2 gene testing is more directly relevant.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Her 2/Neu gene</strong> amplification is <strong>associated with breast cancer aggressiveness </strong>and <strong>treatment decisions </strong>but is not a part of routine genetic screening for hereditary breast and ovarian cancer syndrome.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C-myc</strong> is an <strong>oncogene implicated </strong>in the <strong>pathogenesis of various cancers</strong>, including <strong>breast cancer</strong>, but it does not have a direct role in hereditary breast and ovarian cancer syndromes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA2 genetic testing </strong>is indicated in a patient with a <strong>breast mass </strong>and a <strong>family history of ovarian carcinoma</strong>, as <strong>mutations </strong>in the <strong>BRCA1 and BRCA2 genes </strong>are strongly associated with <strong>hereditary breast </strong>and <strong>ovarian cancer syndromes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1058</span></strong></span></span></p>",
      "correct_choice_id": 67481,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16881,
      "choices": [
        {
          "id": 67484,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham</span></span></span></p>"
        },
        {
          "id": 67485,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Birmingham</span></span></span></p>"
        },
        {
          "id": 67486,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cunningham</span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></span></p>"
        },
        {
          "id": 67487,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Welham</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All invasive breast carcinomas are graded histologically with the following scoring system:</span></span></p>",
      "unique_key": "Q4197855",
      "question_audio": null,
      "question_video": null,
      "map_id": 32336,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nottingham</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast carcinomas </strong>are histologically graded using the <strong>Nottingham Histologic Score</strong>, also known as the <strong>Nottingham Combined Histologic Grade </strong>or <strong>Nottingham Grading System</strong>. This system evaluates <strong>three histologic features</strong>: <strong>tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>. Each component is assigned a score, and the scores are combined to determine the overall grade. This grading system helps in predicting the behavior and prognosis of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Histologic Score </strong>is used for <strong>grading breast carcinomas</strong>. It <strong>assesses tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>, each of which is given a score.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1064</span></strong></span></span></p>",
      "correct_choice_id": 67484,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41589,
      "choices": [
        {
          "id": 166044,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate hormonal therapy with tamoxifen</span></span></span></p>"
        },
        {
          "id": 166045,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer chemotherapy with doxorubicin and cyclophosphamide</span></span></span></p>"
        },
        {
          "id": 166046,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prescribe trastuzumab </span></span></span></p>"
        },
        {
          "id": 166047,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recommend radiotherapy for local control</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a palpable lump in her left breast. A biopsy is performed, and the histopathological examination reveals invasive ductal carcinoma. Immunohistochemistry (IHC) shows a HER2/neu score of 3+. What is the most appropriate next step in managing this patient&#39;s breast cancer?</span></span></p>",
      "unique_key": "Q6733957",
      "question_audio": null,
      "question_video": null,
      "map_id": 32337,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Prescribe trastuzumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, given its <strong>ability to target HER2/neu-positive tumors</strong>, would be the most appropriate <strong>next step in management </strong>for a patient with a HER2/neu score of 3+ on IHC.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>hormonal therapy </strong>is an essential part of the <strong>treatment for hormone receptor-positive breast cancer</strong>, the HER2/neu status of the tumor guides the use of targeted therapies such as trastuzumab.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chemotherapy </strong>may be a <strong>component of treatment for breast cancer, </strong>but for HER2/neu-positive tumors, trastuzumab is a key targeted therapy that has been shown to significantly improve outcomes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Radiotherapy </strong>could be part of the <strong>comprehensive treatment for breast cancer</strong>, particularly for local control, but is not directly related to the HER2/neu overexpression finding.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with a <strong>HER2/neu score of 3+ indicating HER2 protein overexpression</strong>, <strong>trastuzumab </strong>is the most appropriate next step for targeted therapy in the management of HER2-positive breast cancer.</span></span></span></p>",
      "correct_choice_id": 166046,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41590,
      "choices": [
        {
          "id": 166048,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An aromatase inhibitor </span></span></span></p>"
        },
        {
          "id": 166049,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator (SERM) like tamoxifen</span></span></span></p>"
        },
        {
          "id": 166050,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-releasing hormone agonist</span></span></span></p>"
        },
        {
          "id": 166051,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progestin therapy</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old postmenopausal woman is diagnosed with estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) invasive lobular carcinoma of the breast. What is the most appropriate adjuvant endocrine therapy for this patient?</span></span></p>",
      "unique_key": "Q4657524",
      "question_audio": null,
      "question_video": null,
      "map_id": 32338,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) An aromatase inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>postmenopausal women </strong>with <strong>hormone receptor-positive breast cancer</strong>, <strong>aromatase inhibitors </strong>(e.g., letrozole, anastrozole, exemestane) are often preferred <strong>over tamoxifen</strong>. <strong>Aromatase inhibitors reduce </strong>the <strong>production of estrogen </strong>and are associated with <strong>improved disease-free survival </strong>in this <strong>population</strong>. <strong>Tamoxifen </strong>is more commonly used in <strong>premenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are typically the <strong>first choice for ER+ breast cancer </strong>in <strong>postmenopausal women </strong>because they are <strong>effective at reducing the amount of estrogen </strong>produced by <strong>adipose </strong>and <strong>other tissues</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen, a SERM</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, can be <strong>used in postmenopausal women </strong>but is often reserved for those who <strong>cannot tolerate aromatase inhibitors </strong>or for premenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gonadotropin-releasing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>hormone agonists</strong> are used in <strong>premenopausal women </strong>to <strong>suppress ovarian estrogen production</strong>, which is not applicable in postmenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Progestin therapy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically used in the treatment of <strong>hormone receptor-positive breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>postmenopausal woman </strong>with <strong>ER+ and PR+ breast cancer</strong>, the most appropriate adjuvant <strong>endocrine therapy </strong>is an <strong>aromatase inhibitor</strong>, which has been shown to be more <strong>effective than tamoxifen </strong>in this patient population.</span></span></span></p>",
      "correct_choice_id": 166048,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16867,
      "choices": [
        {
          "id": 67428,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood vessel penetration by tumor cells</span></span></span></p>"
        },
        {
          "id": 67429,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor cells in lymphatic channels</span></span></span></p>"
        },
        {
          "id": 67430,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphocyte infiltration </span></span></span></p>"
        },
        {
          "id": 67431,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With regard to the malignant behavior of leiomyosarcoma, the most important criterion is:</span></span></p>",
      "unique_key": "Q8762571",
      "question_audio": null,
      "question_video": null,
      "map_id": 32330,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) The number of mitoses per high power field </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most important criterion</strong> for <strong>distinction of leiomyosarcoma </strong>from <strong>leiomyoma </strong>(malignant transformation) is the <strong>number of mitoses present</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ten high power fields </strong>(hpf) are <strong>examined</strong>. If<strong> &gt; 10 mitoses</strong> are seen, it <strong>signifies malignancy</strong>. If <strong>cellular atypia </strong>is also <strong>present</strong>, <strong>&gt; 5 mitoses </strong>are enough to make a <strong>diagnosis of leiomyosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When <strong>distinguishing leiomyosarcoma from leiomyoma</strong>, the <strong>assessment of malignancy </strong>heavily <strong>relies on histological examination</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a key <strong>histological criterion </strong>to determine the <strong>malignant behavior of leiomyosarcoma</strong>. A higher number of mitotic figures usually indicates a more aggressive tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Blood vessel penetration by tumor cells</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>feature observed in malignant tumors</strong>. However, while significant, it is not the most critical factor in diagnosing leiomyosarcoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The presence of tumor cells in lymphatic channels</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is another <strong>indication of potential malignancy </strong>and can signify the spread of cancer, but it&#39;s not the primary criterion for diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lymphocyte infiltration</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is often a <strong>sign of an immune response to the tumor </strong>rather than a direct indication of malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>high mitotic index </strong>is indicative of <strong>aggressive tumor behavior </strong>and <strong>malignancy</strong>, aiding in the <strong>differentiation between benign </strong>and <strong>malignant smooth muscle tumors </strong>such as <strong>leiomyomas </strong>and <strong>leiomyosarcomas</strong>, respectively. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1021</span></strong></span></span></p>",
      "correct_choice_id": 67431,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16873,
      "choices": [
        {
          "id": 67452,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clear cell</span></span></span></p>"
        },
        {
          "id": 67453,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></span></span></p>"
        },
        {
          "id": 67454,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Squamous cell carcinoma</span></span></span></p>"
        },
        {
          "id": 67455,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transitional cell carcinoma</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common subtype of endometrial carcinoma on histopathology is:</span></span></p>",
      "unique_key": "Q7354322",
      "question_audio": null,
      "question_video": null,
      "map_id": 32332,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Adenocarcinoma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>most common subtype</strong> of <strong>endometrial carcinoma. </strong>The <strong>majority of endometrial cancers </strong>are <strong>adenocarcinomas</strong>, and they are often <strong>classified into two main types</strong>: <strong>endometrioid </strong>and <strong>non-endometrioid</strong>. <strong>Endometrioid adenocarcinoma </strong>is the <strong>most common subtype</strong>, while <strong>clear cell</strong>, <strong>squamous cell</strong>, and <strong>transitional cell carcinomas </strong>are <strong>less common subtypes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>majority of endometrial carcinomas </strong>are <strong>adenocarcinomas</strong>, with the <strong>endometrioid type </strong>being the <strong>most prevalent</strong>. It <strong>originates </strong>from the <strong>glandular tissue of the endometrium </strong>and often presents in <strong>postmenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clear Cell:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clear cell carcinoma of the <strong>endometrium </strong>is a <strong>rare subtype </strong>and is typically associated with a <strong>more aggressive behavior </strong>and <strong>worse prognosis </strong>than endometrioid adenocarcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Squamous Cell Carcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Squamous cell carcinoma of the <strong>endometrium </strong>is <strong>exceedingly rare </strong>because the <strong>endometrium normally </strong>does <strong>not contain squamous cells</strong>; they may appear secondary to metaplastic processes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Transitional Cell Carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Transitional cell carcinoma is <strong>another rare subtype </strong>of <strong>endometrial cancer </strong>that <strong>resembles urothelial carcinoma of the bladder</strong>. This type of carcinoma is not commonly found in the endometrium.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:&nbsp; </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Adenocarcinoma</strong>, especially the <strong>endometrioid subtype</strong>, is the most <strong>common </strong>form of <strong>endometrial cancer</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 1010</span></strong></span></span></p>",
      "correct_choice_id": 67453,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}